Home ›
Leukemia Trials ›
NCT05772273
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
Trial Details
NCT ID NCT05772273
Phase NA
Sponsor The First Affiliated Hospital of Soochow University
Status RECRUITING
Cancer Type Leukemia
Interventions Azacitidine Donor lymphocyte infusion Camrelizumab
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
Patients with a diagnosis of AML relapse after allogeneic hematopoietic stem cell transplantation. Adequate organ function. Be able to understand and sign informed consent. Age 18 to 60 years old.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →